Tissue Repair Ltd
Research Tissue Repair Ltd (TRP.AX) on Bullrun: market cap AUD 5.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTRP.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 5.14M
- Financial periodFY2026
- RevenueAUD 559.70K
- Net income-AUD 5.36M
- Free cash flow-AUD 7.55M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 5.14M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 559.70K | -AUD 5.36M | -AUD 7.55M | 100.0% | n/a | AUD 4.77M | n/a | AUD 8.77M |
| FY2025 | n/a | n/a | n/a | n/a | -0.07 | n/a | n/a | n/a |
| FY2024 | AUD 152.24K | -AUD 4.14M | -AUD 4.95M | 100.0% | -0.07 | AUD 23.25M | n/a | AUD 18.04M |
| FY2023 | AUD 3.08K | -AUD 4.17M | -AUD 4.26M | 100.0% | -0.07 | AUD 35.15M | n/a | AUD 21.88M |
| FY2022 | n/a | -AUD 6.84M | -AUD 3.97M | n/a | -0.14 | AUD 25.46M | n/a | AUD 25.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 5.14M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tissue Repair Ltd's market cap?
Tissue Repair Ltd's market capitalization is AUD 5.14M.
What does Tissue Repair Ltd do?
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures.